CO5540294A2 - A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM - Google Patents

A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM

Info

Publication number
CO5540294A2
CO5540294A2 CO03104435A CO03104435A CO5540294A2 CO 5540294 A2 CO5540294 A2 CO 5540294A2 CO 03104435 A CO03104435 A CO 03104435A CO 03104435 A CO03104435 A CO 03104435A CO 5540294 A2 CO5540294 A2 CO 5540294A2
Authority
CO
Colombia
Prior art keywords
combination
cyclphosphamide
carmustine
compositions containing
rapamycin derivative
Prior art date
Application number
CO03104435A
Other languages
Spanish (es)
Inventor
Gary Dukart
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5540294A2 publication Critical patent/CO5540294A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una combinación antineoplásica la cual comprende una cantidad efectiva de un inhibidor mTOR y un agente alquilante antineoplásico.2.- Una combinación la cual comprende un inhibidor mTOR y un agente alquilante antineoplásico útil en la preparación de un medicamento para el tratamiento de un neoplasma.3.- Una composición farmacéutica que comprende un inhibidor mTOR, un agente alquilante antineoplásico y un portador aceptable farmacéuticamente.1. An antineoplastic combination which comprises an effective amount of an mTOR inhibitor and an antineoplastic alkylating agent. 2. A combination which comprises an mTOR inhibitor and an antineoplastic alkylating agent useful in the preparation of a medicament for the treatment of a drug. Neoplasm. 3. A pharmaceutical composition comprising an mTOR inhibitor, an antineoplastic alkylating agent and a pharmaceutically acceptable carrier.

CO03104435A 2001-06-01 2003-11-26 A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM CO5540294A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
CO5540294A2 true CO5540294A2 (en) 2005-07-29

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03104435A CO5540294A2 (en) 2001-06-01 2003-11-26 A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM

Country Status (17)

Country Link
EP (1) EP1392286A2 (en)
JP (1) JP2004532883A (en)
KR (1) KR100875611B1 (en)
CN (1) CN100496485C (en)
AU (2) AU2002259309B2 (en)
BR (1) BR0210101A (en)
CA (1) CA2447732A1 (en)
CO (1) CO5540294A2 (en)
EA (1) EA007530B1 (en)
HU (1) HUP0400006A2 (en)
IL (1) IL158800A0 (en)
MX (1) MXPA03010907A (en)
NO (1) NO20035317L (en)
NZ (1) NZ529877A (en)
PL (1) PL367267A1 (en)
SG (1) SG153647A1 (en)
WO (1) WO2002098416A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527692A (en) 2001-02-19 2005-05-27 Novartis Ag Cancer treatment
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
AR046194A1 (en) 2003-11-04 2005-11-30 Mayo Foundation TREATMENT METHOD OF MANTO CELL LYMPHOMA
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
US20070104721A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2275103B1 (en) * 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
KR20090118999A (en) * 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2310011B1 (en) 2008-06-17 2013-07-24 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
SI2326329T1 (en) 2008-08-04 2017-06-30 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HRP20230315T1 (en) 2009-04-06 2023-05-12 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (en) * 2013-12-27 2014-04-16 刘玉含 Meningeoma nursing medicine and preparation method thereof
CN105168204A (en) * 2015-09-06 2015-12-23 江志鑫 Pharmaceutical composition containing mitomycin and capable of resisting colon cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (en) * 1991-06-18 1996-08-08 American Home Prod Use of rapamycin to treat adult T cell lymphoma / leukemia
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
NZ527692A (en) * 2001-02-19 2005-05-27 Novartis Ag Cancer treatment

Also Published As

Publication number Publication date
CN1646120A (en) 2005-07-27
WO2002098416A3 (en) 2003-03-13
KR20040025923A (en) 2004-03-26
EA007530B1 (en) 2006-10-27
MXPA03010907A (en) 2004-02-17
WO2002098416A2 (en) 2002-12-12
BR0210101A (en) 2004-06-08
AU2008202690A1 (en) 2008-07-10
HUP0400006A2 (en) 2004-04-28
PL367267A1 (en) 2005-02-21
IL158800A0 (en) 2004-05-12
AU2002259309B2 (en) 2008-05-01
CN100496485C (en) 2009-06-10
NZ529877A (en) 2006-08-31
EP1392286A2 (en) 2004-03-03
SG153647A1 (en) 2009-07-29
JP2004532883A (en) 2004-10-28
NO20035317L (en) 2003-12-22
KR100875611B1 (en) 2008-12-24
EA200301319A1 (en) 2004-04-29
NO20035317D0 (en) 2003-11-28
CA2447732A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
CO5540294A2 (en) A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
BR0215184A (en) orally active taxane derivative pharmaceutical compositions having increased bioavailability
HUP0303271A2 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
AR023423A1 (en) ADAMANTAN DERIVATIVES, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HRP20020158B1 (en) Action of synergistic combination
AR035500A1 (en) USE OF CLORPROMAZINE AND PENTAMIDINE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL PACKAGE THAT INCLUDE CHLORPROMAZINE AND PENTAMIDINE.
ES2157881T3 (en) PAROXETINE METHANOSULFONATE.
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
CO4970835A1 (en) INHIBITION OF LIPOPROTEIN OXIDATION
AR035533A1 (en) USE OF AT LEAST AN INHIBITOR OF THE ABSORPTION OF THE STEROLS OR THEIR SALTS, SOLVATOS, PHARMACEUTICALLY ACCEPTABLE DRUGS OR MIXTURES OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SITOSTEROLEMIA, COMPOSITIONS OF THE PHARMACEUTICAL USE
BR0207872A (en) Active agent release compound, composition, unit dosage form and method of administration
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
DK1121127T3 (en) Oral pharmaceutical compositions containing buprenorphine
ATE357928T1 (en) PHARMACEUTICAL COMPOSITION FOR THROMBIN PEPTIDE DERIVATIVES
BRPI0415053A (en) p-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
ES2189252T3 (en) ANALGESIC COMPOSITIONS THAT INCLUDE AN ANTAGONIST OF THE COLECISTOQUININE AND AN OPIOID.
PT1210119E (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPIC ADMINISTRATION
AR032642A1 (en) CHEMOTHERAPICAL COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIODISPONIBILITY.
BRPI0412364A (en) solid pharmaceutical composition comprising amisulpride
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
AR035006A1 (en) DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
AR034142A1 (en) A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed